Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Factors affecting the survival of early COVID-19 patients in South Korea: An observational study based on the Korean National Health Insurance big data

Kyeong Hyang Byeon¹,¹, Dong Wook Kim²,¹, Jaiyong Kim³,⁴, Bo Youl Choi¹,⁵, Boyoung Choi⁶, Kyu Dong Cho²

¹ Department of Preventive Medicine, Hanyang University College of Medicine, Seoul, Republic of Korea
² Health Insurance Research Institute, National Health Insurance Service, Wonju, Republic of Korea
³ Institute of Artificial Intelligence and Big Data in Medicine, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea
⁴ Department of Public Health and Medical Administration, Dongyang University, Yeongju, Republic of Korea

A R T I C L E   I N F O

Article history:
Received 24 December 2020
Received in revised form 22 February 2021
Accepted 24 February 2021

Abstract

Objectives: This study aimed to identify the survival rate and explore factors affecting survival among early COVID-19 patients in South Korea.

Methods: Data reported by the Korea Disease Control and Prevention Agency (KDCA), up to 15 July, when COVID-19 was confirmed were used as research data in connection with the National Health Insurance Service’s (NHIS) national health information database. The final analysis targets were 12,646 confirmed patients and 303 deaths. The survival rate of patients with COVID-19 was estimated through Kaplan-Meier survival analysis. Cox proportional hazard regression analysis was performed to search for factors affecting survival.

Results: When looking at the survival rate by age group for men and women, the 28-day survival rate for men aged >80 years was 77% and 73% at 42 days, while 83% and 81% for women. Men had a worse survival rate than women. For chronic diseases, the highest risk of mortality was observed in malignant neoplasms of the respiratory and urogenital systems, followed by diseases of the urinary system and diabetes.

Conclusions: The number of COVID-19 deaths was highest the next day after initial diagnosis. The case fatality rate was high in males, older age, and chronic diseases.

Introduction

After the first confirmed patient with COVID-19 in Korea occurred on 20 January, a sporadic outbreak occurred mostly from overseas. However, in mid-February, a religious gathering in Daegu caused a group infection by exposure to the COVID-19 virus, and the infection spread nationwide. After that, the incidence of infected patients decreased due to the effect of a social distancing policy, but the spread occurred again due to the Itaewon group infection. A policy of distancing in daily life has been implemented in Korea, but sporadic group infections continue to occur in local communities (Korea Disease Control and Prevention Agency, 2020). According to the data of confirmed COVID-19 in patients from 07 to 20 July 2020, the proportion was high at 41.6% among middle-aged patients aged ≥50 years, and 50% of deaths were in patients aged ≥80 years, which showed high fatality rates. In addition, 97.7% of the deaths were in people who had underlying disease (Korea Disease Control and Prevention Agency, 2020). Prior studies have suggested that this is related to the morbidity of severe COVID-19 in patients with chronic diseases (Rodriguez-Morales et al., 2020; Lee et al., 2020) and that the underlying disease may be a risk factor for severely ill patients (Yang et al., 2020). In addition, a lower survival rate was observed in those aged ≥75 years, which was identified as a factor that increased the risk of death (Feng et al., 2020). Males had a higher case fatality rate, and the survival rate was lower in men than in women (Alkhouri et al., 2020; Moon et al., 2020). Studies have also shown that the

https://doi.org/10.1016/j.ijid.2021.02.101
1201-9712/© 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Survival rate decreases in cases aged >60 years, and those with cerebrovascular disease, diabetes, hematologic disease, neurological disease, kidney disease, etc.; these factors have been shown to affect death (Sousa et al., 2020).

Overseas studies have been conducted on the factors affecting the survival rate and risk of death. Various risk factors of patients diagnosed with COVID-19 have been studied through survival analysis that considered the time course from the time symptoms appeared (Alkhouli et al., 2020; Feng et al., 2020; Sousa et al., 2020). It was difficult to find studies from Korea that were related to survival analysis of COVID-19 patients, and considering the symptoms and number of days from diagnosis to death. Therefore, through survival analysis that reflected the time until death after diagnosis of patients with COVID-19, this study aimed to use basic data to reduce the incidence of COVID-19 and the risk of death. The survival rate was identified by socioeconomic factors and chronic diseases, and factors that affect survival were explored. The study aimed to: identify the survival period and epidemiological characteristics of patients with confirmed COVID-19; check the effect of chronic disease in patients with confirmed COVID-19 on death; determine the survival rate of patients with confirmed COVID-19; and explore various factors affecting the survival of patients with confirmed COVID-19.

Methods

Data reported by the Korea Disease Control and Prevention Agency (KDCA), up to 15 July, when COVID-19 was confirmed were used as research data in combination with the National Health Insurance Service’s (NHIS) national health information database (Korea Disease Control and Prevention Agency, 2020: National Health Insurance Sharing Service, 2020). The data reported by the KDCA were of patients who had been confirmed positive by a COVID-19 PCR test at public health centers and medical institutions in the reported area. These reports are epidemiological data collected by the KDCA and created as a database. In addition, data on early COVID-19–confirmed cases in Korea were mostly collected from the outbreaks in Daegu and Gyeongbuk.

Socioeconomic factor variables were extracted from the income level and death status variables reflecting gender, age, residential area, and insurance type by linking with the population tables and the insurance tables of the NHIS database. The variable for the presence of chronic diseases was linked to the claim data table, and a variable for the presence or absence of chronic diseases was made using the cases requested for hospitalization for >3 days, >4 outpatient visits, and >28 days of medication days due to principal or other diagnosis. In addition, if there was a claim for the confirmed patient, the claim data from the sickness details table were used and the date of initial diagnosis was used as the start date of medical treatment. However, if a confirmed patient’s claim did not exist, the initial diagnosis estimate date was made as follows: the first diagnostic estimation date was generated using the sequence of serial numbers and the date before and after the claim existed. In other words, an estimated date was created only if the date without a claim was between the previous date and subsequent dates.

Most initial COVID-19 cases occurred in outbreaks in Daegu and Gyeongbuk in Korea. Due to the lack of beds at medical institutions, some mild patients were treated at the Community Treatment Center designated by the country. COVID-19 patients treated at the Community Treatment Center did not have a first diagnosis date because claim data did not exist. However, since Korea has a national health insurance system, it was possible to identify the socioeconomic factors and chronic diseases of the COVID-19 patients through claim data. The final analysis targets were 12,646 patients with confirmed COVID-19 linked to the corporation data from the confirmed patients reported by the KDCA: 5356 (42.35%) were male and 7290 (57.65%) were female. The study's selection process is shown in Figure 1.

The data reported by the KDCA and the NHIS database were linked to see the difference between the general characteristics of patients with confirmed COVID-19 and whether they died or not,
analyzed with Chi-square test ($\chi^2$ test) and the crude death rate (CDR) was found. In addition, multivariable logistic regression was performed to find the chronic diseases that affected the risk of death, and the odds ratio (OR) and 95% confidence interval (95% CI) were calculated. Lastly, the survival rate of patients with COVID-19 was estimated through Kaplan-Meier survival analysis. To search for factors affecting survival, Cox proportional hazard regression analysis was performed and 95% CI was calculated. Time-considered analysis was conducted in order to calculate an accurate result as to whether the presence or absence of chronic diseases affected the mortality hazard ratio.

All analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA), and the statistical significance level was expressed as a $P$-value of <0.05.

### Results

**Epidemiologic characteristics and the elapsed date of death in COVID-19 patients**

Using the difference between the estimated date of initial diagnosis and the date of death, the number of patients who died according to the elapsed date of death was the most common, with 20 patients who died the next day after the initial diagnosis (Figure 2). The next highest number of deaths was between 3–11 days, which was 70% of the number of deaths included in the 30th day of death. The case fatality rate was 2.97% for males, which was higher than that for females (Table 1). In age groups, the number of deaths was highest in those aged >80 years, with 162 people, and the case fatality rate was highest in those aged >80 years, with 26.34%, followed by those aged 70–79 year, with 8.93%. According to region, the number of confirmed cases was the highest in metropolitan cities; the case fatality rate was highest with 4.53% in rural areas. On the other hand, the case fatality rate was the lowest in metropolitan cities. In the income level reflecting the type of insurer, the number of confirmed cases was the highest when the income level was the lowest while being an employee. The mortality rate was the highest in medical benefits, with self-employed at the highest level of income at 3.40%, and self-employed at the lowest level of income at 3.19%.

**Chronic diseases affecting the death of patients with confirmed COVID-19**

After analyzing the comorbidities that affected the risk of death according to 298 disease classification groups, the risk of death was reviewed by grouping the chronic diseases that were statistically significant into the large and medium classification criteria (Supplementary Table 1). Of 30 chronic diseases, 17 affected the risk of death as follows: malignant neoplasm of larynx; malignant neoplasm of trachea, bronchus and lung; other malignant neoplasms of respiratory and intrathoracic organs; Hodgkin’s disease; non-Hodgkin’s lymphoma; leukemia; other malignant neoplasms of lymphoid, hematopoietic and related tissue 4.30 times; acute and rapidly progressive nephritic syndromes; other glomerular diseases, renal tubulo-interstitial diseases, renal failure 2.50 times; malignant neoplasm of cervix uteri; malignant neoplasm of other and unspecified parts of uterus; other malignant neoplasms of female genital organs; malignant neoplasm of prostate; other malignant neoplasms of male genital organs; malignant neoplasm of bladder; other malignant neoplasms of urinary tract 2.41 times; and diabetes mellitus 2.09 times higher risk of death.

### 28. -day survival rate according to socioeconomic factors of patients with confirmed COVID-19

When looking at the survival rate by age group for men and women, the 28-day survival rate for men aged >80 years was 77%, 75% at 35 days, and 73% at 42 days, while 83%, 82%, and 81% for women, respectively (Supplementary Table 2, Figures. 3 and 4). In city, county, and district, the survival rate was low in the county, and the survival rate was low in recipients of medical benefits in terms of income level.

### 28. -day survival rate by chronic disease among patients with confirmed COVID-19

The survival rate was lowest in order as listed: dementia; Parkinson’s disease; Alzheimer’s disease; malignant neoplasm of larynx; malignant neoplasm of trachea, bronchus and lung; other malignant neoplasm of respiratory and intrathoracic organs; malignant neoplasm of cervix uteri; malignant neoplasm of other and unspecified parts of uterus; other malignant neoplasms of female genital organs; malignant neoplasm of prostate; other malignant neoplasms of male genital organs; malignant neoplasm of bladder; other malignant neoplasms of urinary tract; other hypertensive diseases, intracranial hemorrhage, cerebral infarction, stroke, not specified as hemorrhage or infarction; other cerebrovascular disease (Supplementary Table 3).

**Socioeconomic factors affecting the survival of patients with confirmed COVID-19**

In Model 2, which calibrated for socioeconomic factors and chronic diseases, the mortality hazard ratio of men was 2.25 times higher than that of women (Table 1). For age groups: 50–59 years were 8.72 times, 60–69 years were 19.36 times, 70–79 years were 64.84 times, and ≥80 years were 150.97 times higher than those aged <49 years. In the case of income level, when only socioeconomic factors were calibrated, the mortality hazard ratio was 1.55 times higher in medical benefits, but when socioeconomic factors and chronic diseases were calibrated, it was not statistically significant.

![Figure 2](image-url) Cumulative proportion and distribution of the elapsed date of death in the mortality group with confirmed COVID-19.
Table 1
Epidemiologic characteristics and socioeconomic factors affecting the survival of patients with confirmed COVID-19.

| Socioeconomic factors | COVID-19 patients | Hazard ratio of mortality |
|-----------------------|-------------------|--------------------------|
|                       | Confirmed | deaths | CDR | Model 1 | Model 2 |
|                       |           |         |     | HR (95% CI) | HR (95% CI) |
| Sex                   |           |         |     |         |         |
| Male                  | 5,197     | 159     | 0.030 | 2.08 (1.65–2.62) | 2.25 (1.77–2.86) |
| Female                | 7,146     | 144     | 0.020 | Ref | Ref |
| Age group, years      |           |         |     |         |         |
| ≤49                   | 7,075     | 5       | 0.001 | Ref | Ref |
| 50–59                 | 2,266     | 17      | 0.007 | 11.22 (4.13–30.42) | 8.72 (3.20–23.77) |
| 60–69                 | 1,743     | 40      | 0.022 | 31.68 (12.48–80.38) | 19.36 (7.52–49.82) |
| 70–79                 | 806       | 79      | 0.089 | 134.39 (54.36–332.20) | 64.84 (25.47–165.05) |
| ≥80                   | 453       | 162     | 0.263 | 454.70 (186.29–1,109.86) | 150.97 (58.70–388.26) |
| Region                |           |         |     |         |         |
| Metropolitan          | 9,097     | 191     | 0.021 | Ref | Ref |
| Non-Metropolitan      |           |         |     |         |         |
| Rural areas           | 1,286     | 61      | 0.045 | 1.32 (0.98–1.77) | 1.12 (0.83–1.53) |
| Health insurance      |           |         |     |         |         |
| Premium level         |           |         |     |         |         |
| Medical aid           | 940       | 56      | 0.056 | 1.55 (1.03–2.35) | 1.42 (0.93–2.18) |
| Self-employed lowest  | 851       | 28      | 0.032 | 1.28 (0.78–2.09) | 1.28 (0.77–2.12) |
| Self-employed low     | 692       | 12      | 0.017 | 1.01 (0.52–1.94) | 1.11 (0.57–2.14) |
| Self-employed middle  | 610       | 12      | 0.019 | 0.80 (0.42–1.53) | 0.83 (0.43–1.59) |
| Self-employed high    | 633       | 13      | 0.020 | 0.95 (0.51–1.80) | 1.02 (0.54–1.93) |
| Self-employed highest | 568       | 20      | 0.034 | 0.97 (0.56–1.67) | 1.12 (0.65–1.94) |
| Employee lowest       | 1,935     | 37      | 0.019 | 0.97 (0.61–1.53) | 0.98 (0.62–1.55) |
| Employee low          | 1,817     | 36      | 0.019 | 1.11 (0.70–1.77) | 1.21 (0.76–1.93) |
| Employee middle       | 1,571     | 23      | 0.014 | 0.79 (0.47–1.32) | 0.85 (0.50–1.44) |
| Employee high         | 1,268     | 28      | 0.022 | 0.82 (0.50–1.34) | 0.78 (0.47–1.29) |
| Employee highest      | 1,458     | 38      | 0.025 | Ref | Ref |

CDR = crude death rate, HR = hazard ratio, CI = confidence interval

* Model 1: Adjusted HR and 95% CI for socioeconomic factors (sex, age, region, health insurance premium level).
† Model 2: Adjusted HR and 95% CI for socioeconomic factors, chronic diseases.

Discussion

COVID-19 can cause mild to severe symptoms and has a higher risk of progressing to severe conditions in the elderly and/or those with underlying disease. They are likely to require intensive treatment if they have COVID-19, and it is estimated that the duration of death, which begins with infection and progresses to death, will be short (Zhou F et al.). In a retrospective cohort study in Wuhan, China, 54 deaths were found to have developed symptoms and the time to death was 18.5 days, along with 36 confirmed cases with comorbidities (Zhou et al., 2020). In the current study, among 303 deaths, the largest number of patients died within 1 day from the estimated date of initial diagnosis to death, followed by 3–11 days, of which 50% of the deaths within 15 days were included. In the case of domestic deaths, it is necessary to explore the risk factors that cause death, to reduce the number of deaths and increase the survival rate in elderly people and those with underlying diseases because the time to death is short and most of them are accompanied by underlying diseases. Thus, this study identified the survival rate of patients with COVID-19 by socioeconomic factors and chronic diseases, and various factors that influence survival.

It was shown that the survival rate for men and women was lower in all age groups >80 years, and the survival rate was lower in men than in women. In chronic diseases, the survival rate was low in patients with dementia, Parkinson’s disease, Alzheimer’s disease, sepsis, and malignant neoplasms of the respiratory system. In addition, the mortality hazard ratio was 2.25 times higher in men than in women, and the older the age group, the higher the mortality hazard ratio. In this study, in order to find out the mortality hazard ratio in all age groups, the HR of the elderly age group was high because the reference was set to be under 40. In chronic diseases, the highest risk of mortality was observed in Alzheimer’s disease 1.38 times; acute myocardial infarction; other ischemic heart diseases, conduction disorders and cardiac arrhythmias; heart failure and other heart diseases 1.31 times (Table 2).

Chronic diseases affecting the survival of patients with confirmed COVID-19

In Model 2, which calibrated for socioeconomic factors and chronic diseases, the following had a high hazard ratio of death: malignant neoplasm of larynx; malignant neoplasm of trachea, bronchus and lung; other malignant neoplasm of respiratory and intrathoracic organs 3.46 times; malignant neoplasm of cervix uteri; malignant neoplasm of other and unspecified parts of uterus; other malignant neoplasms of female genital organs; malignant neoplasm of prostate; other malignant neoplasms of male genital organs; malignant neoplasm of bladder; other malignant neoplasms of urinary tract 2.00 times; acute and rapidly progressive nephritic syndromes; other glomerular diseases; renal tubulo-interstitial diseases; renal failure 1.71 times; diabetes mellitus 1.50 times; dementia; Parkinson’s disease;...
malignant neoplasms of the respiratory and urogenital systems, followed by diseases of the urinary system and diabetes.

In the study by Sousa et al., as a result of a survival analysis by age and with or without comorbidity, elderly, neurologic disease, pneumopathies, and cerebrovascular disease were found to be factors that contributed to the risk of death, which is consistent with the current results that elderly patients and those with comorbidities had a shorter survival period (Sousa et al., 2020). In the results of multiple regression analysis by Moon et al., those aged >70 years, malignancy, and diabetes were contributing factors to death, which were consistent with the results of this study (Moon et al., 2020). In the study by Lee et al., the mortality rate was high in men, and in patients with diabetes, chronic lung disease, and chronic neurologic disease; cancer was not a risk factor. Lee et al. included 98 hospital patients aged ≥65 years in their study; therefore a sufficient number of samples was not available. However, since the current study was conducted on confirmed COVID-19 patients of all ages, it is believed that there is a difference (Lee et al., 2020). In the study by Alkhouri et al., which looked at the gender difference in the mortality rates of COVID-19, the mortality rate of men was also high, and the survival probability before and after PSM (propensity score matching) was shown to be lower in men than in women. It was concluded that this difference cannot be fully explained, as there was a higher prevalence of comorbidities among men. Additional studies are required that stratify males and females to look at the risk of mortality due to various factors (Alkhouri et al., 2020).

In a retrospective Chinese cohort study of 26 cancer patients diagnosed with COVID-19, 53.6% had serious clinical symptoms and 28.6% died, which concluded and explained the deteriorated condition and poor prognosis; it is thought that cancer increases the risk of death among the chronic diseases of patients with confirmed COVID-19 (Zhang et al., 2020). In this study, malignant neoplasm of the respiratory and genitourinary systems increased the HR. However, because the number of deaths for COVID-19 with cancer was small, the confidence interval was wider than that of other chronic diseases. Previous studies have suggested that patients with severe COVID-19 have a high prevalence of diabetes (Arentz et al., 2020; Wang et al., 2020a). In the study by Yan et al., the survival rate of patients with severe COVID-19 with diabetes was lower than for those without diabetes, and the patients who died from severe COVID-19 with diabetes had a high level of inflammation (hsCRP). The large number of patients treated with mechanical ventilation treatment and intensive care unit (ICU) is thought to suggest that diabetes may be a risk factor for death in patients with COVID-19 (Yan et al., 2020). In foreign literature, a high prevalence of kidney and heart disease was observed in patients with COVID-19, and damage to the myocardium had a significant association with a decrease in survival rate. As patients with myocardium damage show high risk of death, both diseases are considered to be variables, with high risk of death in patients with COVID-19 (Arentz et al., 2020; Rodriguez-Morales et al., 2020; Wang et al., 2020b).

According to early studies in China after the outbreak of COVID-19, most deaths from COVID-19 in 2019 were in adults aged >60 years and people with serious underlying diseases. In the case of the United States, according to the results of an initial report, the mortality rate in those aged >65 years was highest among the above, followed by 65–84 years, and the number of hospitalizations and ICU admissions was highest among those aged 65–74 years (Anon, 2020a, 2020b). In Korea, the mortality rate was 79% among those aged >70 years and in the 296 COVID-19 patients who died, and there were more severe patients in the 70–79 years age group (Korea Disease Control and Prevention Agency, 2021) COVID-19 is a serious disease with high hospitalization, ICU hospitalization, and mortality among the elderly, so it is necessary to be active in policy measures such as social distancing to slow the spread of COVID-19 and protect elderly subjects.

Limitations of this study were: first, since the NHIS data is billing data, diagnosis information could only be confirmed by the disease code. The diagnosis of comorbidity in patients with COVID-19 was extracted using the conditions of hospitalization for ≥3 days, outpatient visits for ≥4 days, and medication days for ≥28 days as an annual principal or secondary diagnosis, thereby increasing the validity of the diagnosis information of the claim data. Second, if a patient was diagnosed with COVID-19, did not visit a medical institution, and went to a living treatment center to receive treatment, the claim for treatment did not exist, so there was no treatment start date. For these patients, since the initial diagnosis date was the estimated date of the initial diagnosis made using the attempts and serial numbers of the reporting agency, there was a possible slight difference from the actual diagnosis date.

This study established the basis for evaluating the clinical progress of COVID-19 outbreak patients in Korea. Objective and more accurate initial diagnosis date information and various socioeconomic factors, such as income level, death status, residential area, and chronic diseases, can be found by linking COVID-19 patients' report data and health insurance claim data. Based on this, it was possible to submit more rigorous results that corrected the survival rate and factors affecting it, not a simple case fatality rate that did not take time into account. Among the confirmed cases of COVID-19, survival rates were low and the risk of death was high in older patients and those with chronic diseases. Knowing the mortality rate of COVID-19 and the survival rate of patients can identify the risk factors for death. It is therefore possible to provide professional management for prevention of death from COVID-19, and it is expected that measures to minimize the risk of serious progression can be sought. In addition, it is believed that early diagnosis and timely treatment are necessary for the elderly and people with chronic diseases. In this group of patients, since the history of death is short, a rapid treatment delivery system is necessary, which ensures that patients are treated immediately at the time of diagnosis and medical resources are available.

Ethics approval and consent to participate

This study was exempted from deliberation by the Yonsei University Institutional Review Board (IRB) for the exemption from
| Classification                  | Classification of 298 diseases                                                                 | Chronic diseases (-) | Chronic diseases (+) | Hazard ratio of mortality |
|--------------------------------|-----------------------------------------------------------------------------------------------|----------------------|----------------------|---------------------------|
|                                |                                                                                               | Confirmed Deaths     | Confirmed Deaths     | Model 1 HR (95% CI)       | Model 2 HR (95% CI)       |
| Neoplasms                      | Malignant neoplasm of larynx; malignant neoplasm of trachea, bronchus and lung; other         | 12,313 290 30        | 13 3.06              | (1.73–5.42)               | 3.46 (1.83–6.56)          |
|                                | malignant neoplasms of respiratory and intrathoracic organs                                 |                      |                      |                           |                           |
|                                | Malignant neoplasm of cervix uteri; malignant neoplasm of other and unspecified parts of       | 12,263 288 80        | 15 2.02              | (1.19–3.42)               | 2.00 (1.17–3.41)          |
|                                | uterus; malignant neoplasms of female genital organs; malignant neoplasm of prostate; other   |                      |                      |                           |                           |
|                                | malignant neoplasms of male genital organs; malignant neoplasm of bladder; other malignant   |                      |                      |                           |                           |
|                                | neoplasms of urinary tract                                                                   |                      |                      |                           |                           |
|                                | Malignant neoplasm of other, ill-defined, secondary, unspecified and multiple sites           | 12,146 291 197       | 12 1.71              | (0.96–3.05)               | 1.15 (0.59–2.22)          |
|                                | Hodgkin’s disease; Non-Hodgkin’s lymphoma; leukemia; other malignant neoplasms of lymphoid,   |                      |                      |                           |                           |
|                                | hematopoietic and related tissue                                                              |                      |                      |                           |                           |
|                                | Diabetes mellitus                                                                            | 11,009 156 1,334     | 147 1.86             | (1.48–2.34)               | 1.50 (1.18–1.92)          |
|                                |                                                                                               |                      |                      |                           |                           |
| Endocrine, nutritional and    | Dementia; Parkinson’s disease; Alzheimer’s disease                                            | 11,876 175 467       | 128 1.66             | (1.26–2.19)               | 1.38 (1.03–1.84)          |
| metabolic diseases             | Schizophrenia; schizotypal and delusional disorders; mood disorders; neurotic, stress-related |                      |                      |                           |                           |
|                                | and somatiform disorders                                                                     | 10,333 168 2,010     | 135 1.42             | (1.12–1.80)               | 1.09 (0.84–1.42)          |
|                                | Other mental and behavioral disorders; inflammatory diseases of the central nervous system;   |                      |                      |                           |                           |
|                                | multiple sclerosis                                                                           | 11,367 222 976       | 81 1.53              | (1.17–2.01)               | 1.30 (0.97–1.75)          |
|                                |                                                                                               |                      |                      |                           |                           |
| Mental and behavioral disorders| Epilepsy; transient cerebral ischemic attacks and related syndromes; cerebral palsy and     | 11,799 239 544       | 64 1.29              | (0.97–1.71)               | 1.07 (0.79–1.45)          |
|                                | other paralytic syndromes                                                                    |                      |                      |                           |                           |
|                                | Nerve, nerve root and plexus disorders; other diseases of the nervous system                  | 10,467 147 1,876     | 156 1.45             | (1.14–1.83)               | 1.13 (0.88–1.45)          |
| Diseases of the nervous system | Essential (primary) hypertension                                                               | 10,006 78 2,337      | 225 1.72             | (1.31–2.28)               | 1.30 (0.96–1.75)          |
|                                | Other hypertensive diseases                                                                   | 11,904 227 439       | 76 1.55              | (1.19–2.04)               | 1.18 (0.88–1.57)          |
|                                | Acute myocardial infarction; other ischemic heart diseases; conduction disorders and cardiac   | 11,516 184 827       | 119 1.58             | (1.24–2.01)               | 1.31 (1.02–1.69)          |
|                                | arrhythmias; heart failure; other heart diseases                                              |                      |                      |                           |                           |
|                                | Intracranial hemorrhage; cerebral infarction; stroke, not specified as hemorrhage or         | 11,696 197 647       | 106 1.45             | (1.13–1.86)               | 1.16 (0.88–1.52)          |
|                                | infarction; other cerebrovascular diseases                                                    |                      |                      |                           |                           |
|                                | Pulmonary embolism; atherosclerosis; other peripheral vascular diseases; arterial embolism    | 11,637 213 706       | 90 1.36              | (1.06–1.76)               | 1.11 (0.85–1.44)          |
|                                | and thrombosis; other diseases of arteries, arterioles and capillaries; phlebitis, thrombo-   |                      |                      |                           |                           |
|                                | phlebitis, venous embolism and thrombosis                                                    |                      |                      |                           |                           |
| Diseases of the circulatory   |                                                                                               | 11,846 247 497       | 56 2.18              | (1.62–2.94)               | 1.71 (1.26–2.32)          |
| system                        | Acute and rapidly progressive nephritic syndromes; other glomerular diseases; renal tubulo-   |                      |                      |                           |                           |
|                                | interstitial diseases; renal failure                                                          |                      |                      |                           |                           |

HR = hazard ratio, CI = confidence interval

a Model 1: Adjusted HR and 95% CI for socioeconomic factors (sex, age, region, health insurance premium level).

b Model 2: Adjusted HR and 95% CI for socioeconomic factors, chronic diseases.
IRB deliberation that does not include personally identifiable information (CR320311).

Availability of data and materials

The dataset used and analyzed in this study is provided upon request for data customized to the National Health Insurance Service.

Competing interests

The authors have no potential conflicts of interest to disclose.

Funding

This work was supported by the Government-wide R&D Fund project for infectious disease research (GFID), Republic of Korea (grant number: HG18C0088).

Authors’ contributions

Kim J, Byeon KH, and Choi BY designed the study; Kim DW and Cho KD contributed to data acquisition; Kim J, Kim DW, and Byeon KH carried out the statistical analysis; Byeon KH drafted the manuscript; Choi B revised the manuscript. All authors contributed to the interpretation of data and revision of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We thank all of the people who are struggling in healthcare fields to overcome the COVID-19 outbreak. In addition, we would like to thank the epidemiological team of the Korea Disease Control and Prevention Agency for providing registry data for the study. This study was performed under the research project named ‘Research and Development on Integrated Surveillance System for Early Warning of Infectious Diseases (RISEWIDs)’.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.ijid.2021.02.101.

References

Anon. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua liu xing bing xue za zhi 2020;402(1D S2):41(2);145–51.
Anon. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep 2020;69(12):343–6.
Alkhouli M, Nanjundappa A, Annie F, Bates MC, Bhatt DL. Sex differences in case fatality rate of COVID-19: insights from a multinational registry. Mayo Clin Proc 2020;95(8):1613–20.
Arendt M, Yim E, Klaflf L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA 2020;.
Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with different severities: a multicenter study of clinical features. Am J Respir Crit Care Med 2020;201 (11):1380–8.
KDCA portal; Available from: http://www.cdc.go.kr/CDC/main.jsp. [Accessed Sep 25 2020].
Korea Disease Control and Prevention Agency. Current Status of Coronavirus Disease 2019 in Korea. 2020 Available from: http://www.cdc.go.kr/index.es?sid=az. [Accessed Aug 30 2020].
Lee JY, Kim HA, Huh K, Hyn M, Rhee J-Y, Jang S, et al. Risk factors for mortality and respiratory support in elderly patients hospitalized with COVID-19 in Korea. J Korean Med Sci 2020;35(23).
Moon S-S, Lee K, Park J, Yun S, Lee YS, Lee DS. Clinical characteristics and mortality predictors of COVID-19 patients hospitalized at nationally-designated treatment hospitals. J Korean Med Sci 2020;35(36).
National Health Insurance Sharing Service. NHIS portal. 2020 Available from: https://nghs.nhiss.or.kr/bd/aby/brdaya001w.do. [Accessed May 10 2019].
Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, Villanizar-Pena R, Holguin-Rivera Y, Escalera-Anteza JP, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis 2020;101623.
Sousa CJR, Garces TS, Cestari YRF, Florêncio RS, Moreira TMM, Pereira MIL. Mortality and survival of COVID-19. Epidemiol Infect 2020;148:e123.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323(11):1061–9.
Wang L, He WB, Yu XM, Liu HF, Zhou WJ, Jiang H. [Prognostic value of myocardial injury in patients with COVID-19]. Zhonghua Yan Ke Za Zhi 2019;8(1).
Yan Y, Yang Y, Wang F, Ren H, Zhang S, Shi X, et al. Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. BMJ Open Diabetes Res Care 2020;8(1).
Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis: Off Publ Int Soc Infect Dis 2020;.
Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol 2020;.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England) 2020;395(10229):1054–62.